Hemab Therapeutics Raises $157M in Series C Led by Sofinnova Partners

Why It Matters

The sizable capital raise provides Hemab with the resources to accelerate its clinical programs, underscoring investor confidence in novel coagulation therapies and potentially reshaping treatment options in a high‑need market.

Deal Summary

Hemab Therapeutics completed a multifold oversubscribed $157 million Series C financing led by Sofinnova Partners, with participation from a large long‑only global asset manager, a global sovereign wealth fund, Avoro Capital Advisors and existing backers including RA Capital Management, Novo Holdings and others. Joe Anderson of Sofinnova will join Hemab’s board in connection with the financing.